Alana L. Gibson

Alana L. Gibson

Auto-generated profile, based on publicly available information

Alana L. Gibson

Department of Human Health and Services, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in eLife
Verified
Journal Article
Open access
MTMarkus Terrey
Markus Terrey
SAScott I Adamson
Scott I Adamson
AGAlana L Gibson
Alana L Gibson
TDTianda Deng
Tianda Deng
RIRyuta Ishimura
Ryuta Ishimura
SASusan L Ackerman
Susan L Ackerman
Ribosome-associated quality control pathways respond to defects in translational elongation to recycle arrested ribosomes and degrade aberrant polypeptides and mRNAs. Loss of a tRNA gene leads to ribosomal pausing that is resolved by the translational GTPase GTPBP2, and in its absence causes neuron death. Here, we show that loss of the homologous protein GTPBP1 during tRNA deficiency in the mouse brain also leads to codon-specific ribosome pausing and neurodegeneration, suggesting that these non-redundant GTPases function in the same pathway to mitigate ribosome pausing. As observed in Gtpbp2-/- mice (Ishimura et al., 2016), GCN2-mediated activation of the integrated stress response (ISR) was apparent in the Gtpbp1-/- brain. We observed decreased mTORC1 signaling which increased neuronal death, whereas ISR activation was neuroprotective. Our data demonstrate that GTPBP1 functions as an important quality control mechanism during translation elongation and suggest that translational signaling pathways intricately interact to regulate neuronal homeostasis during defective elongation.

25 October 2016 in Human Molecular Genetics
Verified
Journal Article
Closed access
RCRandy J. Chandler
Randy J. Chandler
IWIan M. Williams
Ian M. Williams
AGAlana L. Gibson
Alana L. Gibson
CDCristin Davidson
Cristin Davidson
AIArturo A. Incao
Arturo A. Incao
CVCharles P. Venditti
Charles P. Venditti
Niemann-Pick disease, type C1 (NPC1) is a heritable lysosomal storage disease characterized by a progressive neurological degeneration that causes disability and premature death. A murine model of NPC1 disease (Npc1-/-) displays a rapidly progressing form of NPC1 disease which is characterized by weight loss, ataxia, increased cholesterol storage, loss of cerebellar Purkinje neurons and early lethality. To test the potential efficacy of gene therapy for NPC1, we constructed adeno-associated virus serotype 9 (AAV9) vectors to deliver the NPC1 gene under the transcriptional control of the neuronal-specific (CamKII) or a ubiquitous (EF1a) promoter. The Npc1-/- mice that received a single dose of AAV9-CamKII-NPC1 as neonates (2.6 × 1011GC) or at weaning (1.3 × 1012GC), and the mice that received a single dose of AAV9-EF1a-NPC1 at weaning (1.2 × 1012GC), exhibited an increased life span, characterized by delayed weight loss and diminished motor decline. Cholesterol storage and Purkinje neuron loss were also reduced in the central nervous system of AAV9 treated Npc1-/- mice. Treatment with AAV9-EF1a-NPC1, as compared to AAV9-CamKII-NPC1, resulted in significantly increased survival (mean survival increased from 69 days to 166 and 97 days, respectively) and growth, and reduced hepatic-cholesterol accumulation. Our results provide the first demonstration that gene therapy may represent a therapeutic option for NPC1 patients and suggest that extraneuronal NPC1 expression can further augment the lifespan of the Npc1-/- mice after systemic AAV gene delivery.

18 August 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
CDCristin Davidson
Cristin Davidson
AGAlana L Gibson
Alana L Gibson
TGTansy Gu
Tansy Gu
LBLaura Baxter
Laura Baxter
BDBenjamin E Deverman
Benjamin E Deverman
WPWilliam J. Pavan
William J. Pavan
Niemann–Pick C1 disease (NPC1) is a rare, fatal neurodegenerative disease caused by mutations in NPC1, which encodes the lysosomal cholesterol transport protein NPC1. Disease pathology involves lysosomal accumulation of cholesterol and lipids, leading to neurological and visceral complications. Targeting the central nervous system (CNS) from systemic circulation complicates treatment of neurological diseases with gene transfer techniques. Selected and engineered capsids, for example, adeno-associated virus (AAV)-PHP.B facilitate peripheral-to-CNS transfer and hence greater CNS transduction than parental predecessors. We report that systemic delivery to Npc1m1N/m1N mice using an AAV-PHP.B vector ubiquitously expressing NPC1 led to greater disease amelioration than an otherwise identical AAV9 vector. In addition, viral copy number and biodistribution of GFP-expressing reporters showed that AAV-PHP.B achieved more efficient, albeit variable, CNS transduction than AAV9 in Npc1m1N/m1N mice. This variability was associated with segregation of two alleles of the putative AAV-PHP.B receptor Ly6a in Npc1m1N/m1N mice. Our data suggest that robust improvements in NPC1 disease phenotypes occur even with modest CNS transduction and that improved neurotrophic capsids have the potential for superior NPC1 AAV gene therapy vectors.

4 June 2021 in eLife
Verified
Journal Article
Open access
MTMarkus Terrey
Markus Terrey
SAScott I Adamson
Scott I Adamson
AGAlana L Gibson
Alana L Gibson
TDTianda Deng
Tianda Deng
RIRyuta Ishimura
Ryuta Ishimura
SASusan L Ackerman
Susan L Ackerman
Terrey M, Adamson SI, Gibson AL, Deng T, Ishimura R, Chuang JH, Ackerman SL. 2020. GTPBP1 resolves paused ribosomes to maintain neuronal homeostasis. eLife 9:e62731. doi: 10.7554/eLife.62731.

30 March 2026 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
AMAvani V Mylvara
Avani V Mylvara
AGAlana L Gibson
Alana L Gibson
TGTansy Gu
Tansy Gu
CDCristin Davidson
Cristin Davidson
AIArturo A Incao
Arturo A Incao
WPWilliam J. Pavan
William J. Pavan
Niemann–Pick disease, type C1 (NPC1), is a rare, fatal neurodegenerative disorder caused by pathological variants in NPC1 , which encodes a lysosomal cholesterol transporter. FDA-approved treatments are limited and do not target the underlying genetic defect. Both systemic and central nervous system delivery of AAV9-h NPC1 have shown significant disease amelioration in NPC1 murine models. To assess the impact of dose in null Npc1 m1N/m1N mice, we systemically administered three different doses of AAV9-h NPC1 at 4 wk old. Then, to assess the impact of age, we administered the medium dose before phenotypic onset or at early or late stage of disease progression (4, 6, or 8 wk old, respectively). Higher vector doses and earlier treatment were associated with significantly increased lifespan, slower disease progression, and enhanced central nervous system transduction. In Npc1 I1061T/I1061T mice, a model recapitulating a common human hypomorphic variant, similar benefits ensued. Our findings help define dose ranges, treatment ages, and efficacy in hypomorphic models of NPC1 deficiency and suggest that higher doses of AAV9-h NPC1 in presymptomatic disease states are likely to yield better outcomes in NPC1 individuals.

8 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAvani V. Mylvara
Avani V. Mylvara
AGAlana L. Gibson
Alana L. Gibson
TGTansy Gu
Tansy Gu
CDCristin Davidson
Cristin Davidson
AIArt A. Incao
Art A. Incao
WPWilliam J. Pavan
William J. Pavan
Niemann-Pick disease, type C1 (NPC1) is a rare, fatal neurodegenerative disorder caused by pathological variants in NPC1 , which encodes a lysosomal cholesterol transport protein. There are no FDA approved treatments for this disorder. Both systemic and central nervous system delivery of AAV9- hNPC1 have shown significant disease amelioration in NPC1 murine models. To assess the impact of dose and window of therapeutic efficacy in Npc1 m1N mice, we systemically administered three different doses of AAV9- hNPC1 at 4 weeks old and the medium dose at pre-, early, and post-symptomatic timepoints. Higher vector doses and treatment earlier in life were associated with enhanced transduction in the nervous system and resulted in significantly increased lifespan. Similar beneficial effects were noted after gene therapy in Npc1 I1061T mice, a model that recapitulates a common human hypomorphic variant. Our findings help define dose ranges, treatment ages, and efficacy in severe and hypomorphic models of NPC1 deficiency and suggest that earlier delivery of AAV9- hNPC1 in a pre-symptomatic disease state is likely to yield optimal outcomes in individuals with NPC1. Summary Blurb: Systemic AAV9- hNPC1 gene therapy in null Npc1 m1N mice at higher doses or with earlier administration and treatment of hypomorphic Npc1 I1061T mice delays disease progression and increases lifespan.